Navigation Links
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Date:4/22/2011

nt VTE, involving approximately 7,500 patients in 450 clinical sites in approximately 40 countries.(2)

Existing anticoagulants include heparins and vitamin K antagonists. Heparins are injectable, which is an important clinical consideration for patients who need long-term treatment. Vitamin K antagonists are given orally, but are associated with numerous drug and food interactions.(3)

Commenting on the future global potential for edoxaban, Kazunori Hirokawa, Global Head of R&D Unit, Daiichi Sankyo, said, "Edoxaban has been shown to be an effective anticoagulant for the prevention of VTE after major orthopedic surgery, with a predictable pharmacokinetic and pharmacodynamic profile, which allows for a convenient, once-daily dosing."

About Venous Thromboembolism

Venous thromboembolism (VTE) is the term for the generation of a blood clot and the obstruction of a vein or a pulmonary artery by a blood clot. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are types of VTE. DVT is a blood clot anywhere in the deep veins of the legs or pelvis. PE is caused by a clot that travels to the lungs, lodging in the pulmonary arteries.

About Edoxaban

Edoxaban is a once-daily oral anticoagulant that directly inhibits Factor Xa, an important factor in the coagulation process. Edoxaban is currently only approved in Japan, licensed for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty, total hip arthroplasty and hip fracture surgery. Daiichi Sankyo continues to develop edoxaban at a global level as a potential new treatment for stroke prevention in atrial fibrillation, and the treatment and prevention of recurrent VTE. Notably, Daiichi Sankyo has more than 25 years experience conducting research in the area of Factor Xa inhibition and was the first company to study these compounds in humans.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
6. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
7. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
10. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
11. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Boehringer Ingelheim will ... disease at the American Thoracic Society International Conference ... , May 17 – 22. Data ... for the treatment of chronic obstructive pulmonary disease ... well as investigational compounds for asthma, idiopathic pulmonary ...
(Date:5/17/2013)... 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 inhibitor ... both dose groups. The primary endpoint assessed the proportion ... with data reported in previous trials, the most common ... results will be presented at an upcoming medical congress. ...
(Date:5/17/2013)... NATICK, Mass. , May 17, 2013  Boston ... to participate at the annual EuroPCR Scientific Program May ... "We are pleased to present a particularly rich and ... Keith Dawkins , M.D., global chief ... several trials will be presented, including the NG PROMUS ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
(Date:5/19/2013)... foodies everywhere have long recognized ginger as a great ... sweet and savory dishes; now, a study from researchers ... root also may have properties that help asthma patients ... will be presented at the ATS 2013 International Conference. ... the bronchial tubes that carry air into and out ...
(Date:5/19/2013)... People in Minnesota have a great option ... offering its 28 Day Fat Loss Formula. The best ... of their own home. The product sells for $135 dollars ... be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is ... now, but after using the 28 Day Fat Loss Formula ...
(Date:5/19/2013)... 19, 2013 Today, Zane Benefits, ... business health insurance . Zane Benefits, which provides ... health benefits, is the leader in health care ... reimbursement arrangements . , According to Zane Benefits’ ... intrinsically know the value of small business health ...
(Date:5/19/2013)... These molecular diagnostics market reports provide ... Italy, Germany and France:,     Major ... as well as key economic, regulatory, demographic, social ... the next five years. ,     An extensive ... formats, detection methodologies, trends in testing automation and ...
(Date:5/19/2013)... Americans live closer to their dogs than ... Medical Association (AVMA) U.S. Pet Ownership and Demographics Sourcebook, ... dog a member of the family, up from the ... years earlier. , According to the American Pet Products ... dedicated to pets has increased every year without interruption, ...
Breaking Medicine News(10 mins):Health News:Ginger compounds may be effective in treating asthma symptoms 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3
... May 20 - XanGo, LLC, the mangosteen beverage category ... icon, former presidential advisor, philanthropist and motivational speaker Doug ... brings to XanGo deep experience in direct selling, having ... the past 30 years. He previously served as special ...
... WILL BE SOLD ON iTUNES TO RAISE FUNDS FOR ... Will Be Donated To D.C.-Based Accelerate Brain Cancer CureLOS ... the seventh season of "American Idol," David Cook returns ... Wednesday night to perform "Permanent," -- a song he ...
... WINNIPEG, May 20 /PRNewswire/ - The Children,s Hospital ... on its newly commissioned RIVA System (Robotic Intravenous ... syringes and bags from Intelligent Hospital Systems (IH ... The Children,s Hospital of Philadelphia was rated first ...
... RALEIGH, N.C. , May 20 ... healthcare grade televisions and on-demand patient and staff interactive ... on-demand video education and entertainment system into ... expanded and renovated its facility, adding two new floors ...
... May 1st, 2009 in TEDA Tianjin, ChinaTEDA Tianjin, China, ... contract manufacturer of API,s and intermediates, and Drug Products ... opening if its high potency Active Pharmaceutical Ingredient (API) ... This dedicated facility is sited at Asymchem,s TEDA Tianjin ...
... and Healthcare Industry Leaders to Measure Impact of Patient ... A group of prominent healthcare leaders, clinicians, researchers ... Institute for Interactive Patient Care (IIPC). ... for the importance of patient engagement as a means ...
Cached Medicine News:Health News:Direct Selling Icon, Former Presidential Advisor Doug Wead Joins XanGo 2Health News:Direct Selling Icon, Former Presidential Advisor Doug Wead Joins XanGo 3Health News:David Cook to Perform 'Permanent' on the American Idol Season Finale Tonight 2Health News:TeleHealth Services Chosen by HCA to Install Interactive Patient Education System in Timpanogos Regional Hospital 2Health News:TeleHealth Services Chosen by HCA to Install Interactive Patient Education System in Timpanogos Regional Hospital 3Health News:TeleHealth Services Chosen by HCA to Install Interactive Patient Education System in Timpanogos Regional Hospital 4Health News:Asymchem Announces Opening of High Potency API and Drug Product Facility 2Health News:Institute for Interactive Patient Care Launched 2Health News:Institute for Interactive Patient Care Launched 3Health News:Institute for Interactive Patient Care Launched 4
... the advantages of the IPL Quantum DL and ... and other deeper vascular lesions. This cost-effective system ... alone device or as an upgrade to the ... range of conditions including: Leg veins ...
... powerful, versatile, and innovative aesthetic treatments to ... Light and Laser System.,With StarLux you attach ... so theres no need to buy ... choose among Laser, Intense Pulsed Light, and ...
... (Western Blot): The assay uses immortalized human ... surface. The cells are fixed to the ... uninfected T-cells are provided as a control. ... HIV- I antibodies comes in contact with ...
... say the most efficient,aspiration is ... movement of the,cannula tip. Rigorous ... ARC-H II Reciprocating Cannula,assures that ... is,restricted to a longitudinal axis ...
Medicine Products: